Key points from article :
Seattle-based biotech firm Oisín Biotechnologies has recently secured $15 million in funding to advance its innovative approach to combatting the effects of aging. Recognizing the growing demand for treatments that address muscle loss, particularly in the wake of popular weight-loss drugs, Oisín has pivoted its focus towards developing genetic medicines specifically designed to enhance muscle mass.
This approach involves utilizing a unique delivery system called Fusogenix PLV, developed by Entos Pharmaceuticals, which allows for the efficient delivery of genetic material directly into cells throughout the body. This technology not only enables effective treatment but also permits safe, repeated dosing, addressing a key challenge in the field.
The recent funding round, led by AbbVie Ventures, the investment arm of pharmaceutical giant AbbVie, signifies a significant vote of confidence in Oisín's potential. The partnership also brings AbbVie's extensive drug development expertise to the table, further strengthening Oisín's position in the race to develop novel therapies for age-related conditions.
